<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="516">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04740580</url>
  </required_header>
  <id_info>
    <org_study_id>H48186</org_study_id>
    <nct_id>NCT04740580</nct_id>
  </id_info>
  <brief_title>Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease</brief_title>
  <official_title>Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Methodist Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key&#xD;
      defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain&#xD;
      glucose uptake are linked to AD. This trial will investigate the effects of supplementing&#xD;
      glycine and N-acetylcysteine vs. alanine as placebo on these defects in AD, and examine the&#xD;
      effects on cognition.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glutathione (GSH) deficiency, oxidative stress, mitochondrial dysfunction, insulin resistance&#xD;
      and inflammation are linked to Alzheimer's disease (AD). In prior studies, investigators have&#xD;
      shown that GSH deficiency contributes to mitochondrial impairment and oxidative stress, and&#xD;
      that GSH deficiency can be corrected by supplementing its precursors glycine and cysteine&#xD;
      (provided as N-acetylcysteine, NAC), with the combination termed GlyNAC.&#xD;
&#xD;
      This randomized clinical trial will evaluate the effect of GlyNAC vs. alanine placebo&#xD;
      supplementation provided for 24-weeks to patients with AD, and measure changes in cognition,&#xD;
      GSH concentrations, oxidative stress, brain glucose uptake, brain inflammation and insulin&#xD;
      resistance.&#xD;
&#xD;
      Participants will be recruited, and enrolled only after meeting eligibility criteria. Before&#xD;
      beginning study supplementation they will undergo imaging studies (MRI, Tau-PET, FDG-PET and&#xD;
      TSPO-PET scans), and only the FDG- and TSPO-PET scans will be repeated after completing&#xD;
      24-weeks of nutrient supplementation. Cognitive measurements, metabolic and mitochondrial&#xD;
      measurements (as described below) will be done before supplementation, and after 12-weeks and&#xD;
      24-weeks of completing supplementation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2022</start_date>
  <completion_date type="Anticipated">May 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2025</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Placebo-controlled trial</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognition</measure>
    <time_frame>Day 0 of supplementation, and 12-weeks and 24-weeks after starting supplementation</time_frame>
    <description>Measured using ADAS-Cog testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain glucose uptake</measure>
    <time_frame>Done before supplementation and 24-weeks after starting supplementation</time_frame>
    <description>Measured using brain FDG-PET scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain inflammation</measure>
    <time_frame>Done before supplementation and 24-weeks after starting supplementation</time_frame>
    <description>Done using brain TSPO-PET scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Activities of daily living</measure>
    <time_frame>Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation</time_frame>
    <description>Measured using the ADCS-ADL scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial fuel oxidation</measure>
    <time_frame>Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation</time_frame>
    <description>Measured using indirect calorimetry in the fasted and post-glucose fed state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red-blood cell glutathione, glycine, cysteine and glutamic aid</measure>
    <time_frame>Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation</time_frame>
    <description>Measured using UPLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress</measure>
    <time_frame>Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation</time_frame>
    <description>Measured as plasma concentrations of TBARS and malondialdehyde</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Damage due to oxidative stress</measure>
    <time_frame>Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation</time_frame>
    <description>Measured as plasma concentration of isoprostanes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory cytokines</measure>
    <time_frame>Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation</time_frame>
    <description>Measured as plasma concentrations of IL6, TNFa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial dysfunction</measure>
    <time_frame>Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation</time_frame>
    <description>Measured as plasma concentrations of sICAM1, sVCAM1, E-selectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of Brain-derived neurotropic factor (BDNF)</measure>
    <time_frame>Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation</time_frame>
    <description>Measured using an ELISA kit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial energetics</measure>
    <time_frame>Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation</time_frame>
    <description>Measured using the Oroboros high-resolution respirometer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Glycine plus N-acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycine and cysteine are amino-acid (protein) precursors of glutathione. Cysteine is provided as N-acetylcysteine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alanine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Alanine is an amino-acid (protein), and not a precursor of glutathione synthesis</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glycine</intervention_name>
    <description>The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)</description>
    <arm_group_label>Glycine plus N-acetylcysteine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)</description>
    <arm_group_label>Glycine plus N-acetylcysteine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Alanine</intervention_name>
    <description>The placebo arm will supplement Alanine</description>
    <arm_group_label>Alanine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 55-85 years;&#xD;
&#xD;
          -  Gradual and progressive memory loss for more than 1 year, with a Montreal Cognitive&#xD;
             Assessment score of 10-20;&#xD;
&#xD;
          -  Tau positivity on PET scan;&#xD;
&#xD;
          -  Availability of a study partner.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hospitalization in past 3 months;&#xD;
&#xD;
          -  known diabetes or use of anti-diabetic medications;&#xD;
&#xD;
          -  untreated thyroid disease;&#xD;
&#xD;
          -  creatinine levels &gt;1.5 mg/dL;&#xD;
&#xD;
          -  hemoglobin concentration &lt;11.0 g/dL;&#xD;
&#xD;
          -  known liver disease, or AST/ALT level &gt;2x ULN;&#xD;
&#xD;
          -  history of stroke, brain tumor, active heart failure or active cancer (removable basal&#xD;
             cell cancers will not be an exclusion criteria);&#xD;
&#xD;
          -  untreated depression or other severe psychiatric disorders;&#xD;
&#xD;
          -  pregnancy or nursing (unlikely in this population)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajagopal V Sekhar, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rajagopal V Sekhar, M.D.</last_name>
    <phone>7137983908</phone>
    <email>rsekhar@bcm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajagopal V Sekhar, MD</last_name>
      <phone>713-798-3908</phone>
      <email>rsekhar@bcm.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2022</verification_date>
  <study_first_submitted>February 2, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>May 26, 2022</last_update_submitted>
  <last_update_submitted_qc>May 26, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Rajagopal V Sekhar</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

